What is the approximate drug price of Pazopanib in 2025?

Pazopanib (also known as pazopanib) is a multi-target tyrosine kinase inhibitor commonly used to treat advanced renal cell carcinoma and soft tissue sarcoma. By2025, the situation of pazopanib in the domestic market will be relatively stable. It has been officially launched and has been included in the national medical insurance directory. Since medical insurance implementation policies and reimbursement ratios vary slightly from place to place, it is best for patients to consult local hospitals or pharmacies for specific medical insurance reimbursement standards before purchasing drugs to understand the actual out-of-pocket costs and greatly reduce the financial burden.

In foreign markets, pazopanib is available as both original and generic drugs. The original drug is produced by GSK (GSK), and the price is relatively high. By2025, the price of pazopanib original drug in overseas markets will be approximately more than 1,000 yuan per box. The specific price may fluctuate slightly due to different supply regions and channels. Compared with the price of tens of thousands of yuan when it was initially launched, today's price is more affordable for patients undergoing long-term treatment, and it also improves the accessibility of the drug.

For patients with limited budget or not fully covered by medical insurance, generic drugs are an affordable option. There are currently Indian and Bangladeshi versions of Pazopanib generics on the market. The ingredients of the drugs are basically the same as the original drugs and the therapeutic effects are similar. In 2025, the price of the Indian and Bangladeshi versions of Pazopanib generics is generally between a few hundred yuan, which greatly reduces the cost of medication for patients. These generic drugs are usually introduced through overseas drug purchasing channels or professional medical institutions, but patients still need to pay attention to the quality and formal sources of the drugs when purchasing.

Overall, 2025The price stratification of pazopanib is obvious: the cost of domestic original drugs has been significantly reduced after being reimbursed by medical insurance, foreign original drugs have remained at a level of more than 1,000 yuan, and the Indian and Bangladeshi versions of generic drugs are more affordable. When patients choose drug purchasing channels, they should take comprehensive considerations based on their own condition, financial situation and doctor's recommendations to ensure that treatment costs are reasonably controlled while ensuring drug quality.

References：https://www.votrient.com/